| 1019 |
Drugs Used in the Management of Adverse Events |
02/06/2024 |
DR-TB and PMDT |
| 1022 |
Eligibility Criteria for the Use of Bedaquiline [Bdq] in MDR/RR-TB Treatment |
02/06/2024 |
DR-TB and PMDT |
| 1024 |
Eligibility Criteria for the Use of Delamanid [Dlm] in MDR/RR-TB Treatment |
02/06/2024 |
DR-TB and PMDT |
| 1037 |
Pre-treatment Evaluation [PTE] of DR-TB Patients |
02/06/2024 |
DR-TB and PMDT |
| 1039 |
Shorter Injectable-containing MDR/RR-TB Regimen: Pre-treatment evaluation and follow-up |
02/06/2024 |
DR-TB and PMDT |
| 1040 |
DR-TB Treatment in Pregnancy: General Considerations |
02/06/2024 |
DR-TB and PMDT |
| 1041 |
Immune Reconstitution Inflammatory Syndrome [IRIS] |
02/06/2024 |
DR-TB and PMDT |
| 1042 |
Common or Relevant Adverse Effects of DR-TB Therapy |
02/06/2024 |
DR-TB and PMDT |
| 1043 |
Management of QT Prolongation by Grade of Severity of ADR |
02/06/2024 |
DR-TB and PMDT |
| 1044 |
Management of Prolonged QTcF During Treatment with Shorter/Longer Oral MDR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
| 1045 |
State PMDT Committee: Terms of Reference [ToR] |
02/06/2024 |
DR-TB and PMDT |
| 1047 |
Management of Hepato-toxicity During Treatment with H Mono/Poly DR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
| 1059 |
Newer Anti-TB Drugs |
02/06/2024 |
DR-TB and PMDT |
| 1060 |
Newer Anti-TB Drugs: Bedaquiline [Bdq] |
02/06/2024 |
DR-TB and PMDT |
| 1104 |
Use of M/XDR-TB Regimen in People Living with HIV [PLHIV] |
02/06/2024 |
DR-TB and PMDT |
| 1064 |
Weight Band-wise Dosages of DR-TB Drugs for Adults |
02/06/2024 |
DR-TB and PMDT |
| 1065 |
Drug-resistant TB Service Linkages to Private Sectors |
02/06/2024 |
DR-TB and PMDT |
| 1066 |
Mandatory Establishment of DR-TB Centres in All Medical Colleges |
02/06/2024 |
DR-TB and PMDT |
| 1067 |
Functions of District DR-TB Centre |
02/06/2024 |
DR-TB and PMDT |
| 1068 |
Requirements for Establishing District DR-TB Centres |
02/06/2024 |
DR-TB and PMDT |
| 1077 |
Baseline Second-line Drug-susceptibility Testing |
02/06/2024 |
DR-TB and PMDT |
| 1093 |
Prevention of Drug-resistance |
02/06/2024 |
DR-TB and PMDT |
| 1094 |
Shorter oral Bedaquiline-containing MDR/RR-TB regimen |
02/06/2024 |
DR-TB and PMDT |
| 1098 |
DR-TB Services Referral Linkage Scenario: Patient Notified from the Private Sector |
02/06/2024 |
DR-TB and PMDT |
| 1099 |
DR-TB Service Referral Linkages Scenario: DR-TB Patient Referred for Treatment from the Private Sector with Bacteriological Confirmation in the Private Sector |
02/06/2024 |
DR-TB and PMDT |
| 1100 |
DR-TB Service Referral Linkages Scenario: DR-TB Patient Referred for Treatment from the Private Sector with Treatment Initiated in the Private Sector |
02/06/2024 |
DR-TB and PMDT |
| 1101 |
Rapid Molecular Drug-resistance Testing |
02/06/2024 |
DR-TB and PMDT |
| 1102 |
Management of Drug-resistant TB |
02/06/2024 |
DR-TB and PMDT |
| 1103 |
Clinical Monitoring of DR-TB Patients |
02/06/2024 |
DR-TB and PMDT |
| 1105 |
Pre-treatment Evaluation [PTE] in Longer Oral M/XDR-TB Regimen |
02/06/2024 |
DR-TB and PMDT |
